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Aims/hypothesis: Interferon regulatory factor (IRF)4 plays a critical role in lymphoid 
development and the regulation of immune responses. Genetic deletion of IRF4 has been 
shown to suppress autoimmune disease in several mouse models, but its role in autoimmune 
diabetes in NOD mice remains unknown. 
Methods: To address the role of IRF4 in the pathogenesis of autoimmune diabetes in NOD 
mice, we generated IRF4-knockout NOD mice and investigated the impact of the genetic 
deletion of IRF4 on diabetes, insulitis and insulin autoantibody; the effector function of T 
cells in vivo and in vitro; and the proportion of dendritic cell subsets. 
Results: Heterozygous IRF4-deficient NOD mice maintained the number and phenotype of T 
cells at levels similar to NOD mice. However, diabetes and autoantibody production were 
completely suppressed in both heterozygous and homozygous IRF4-deficient NOD mice. The 
level of insulitis was strongly suppressed in both heterozygous and homozygous 
IRF4-deficient mice, with minimal insulitis observed in heterozygous mice. An adoptive 
transfer study revealed that IRF4 deficiency conferred disease resistance in a 
gene-dose-dependent manner in recipient NOD/severe combined immunodeficiency mice. 
Furthermore, the proportion of migratory dendritic cells in lymph nodes was reduced in 
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heterozygous and homozygous IRF4-deficient NOD mice in an IRF4 dose-dependent manner. 
These results suggest that the levels of IRF4 in T cells and dendritic cells are important for the 
pathogenesis of diabetes in NOD mice. 
Conclusions/interpretation: Haploinsufficiency of IRF4 halted disease development in NOD 
mice. Our findings suggest that an IRF4-targeted strategy might be useful for modulating 
autoimmunity in type 1 diabetes. 
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Type 1 diabetes is an autoimmune disease that results from the autoreactive destruction of 
insulin-producing beta cells following mononuclear cell infiltration [1]. Studies of NOD mice 
(a well-characterised animal model of type 1 diabetes) have demonstrated that the beta cell 
destruction occurs as a consequence of a breakdown in immune regulation, i.e., activation of 
the innate immune system, expansion of autoreactive CD4+ T cells, CD8+ T cells, and 
autoantibody-producing B cells [2, 3]. However, the precise mechanisms that control this 
autoimmune process are still not clearly understood. 
Interferon regulatory factor (IRF)4 is a transcriptional factor of the IRF family that regulates 
innate and adaptive immune responses [4]. In contrast to other IRFs, IRF4 is preferentially 
expressed in lymphocytes and its expression is not inducible by interferons, but rather by 
antigen receptor-mediated stimulation such as by plant lectins, CD3 or IgM crosslinking [5]. 
A series of reports have documented that IRF4 plays pleiotropic roles in lymphoid 
development and its immune response [6, 7]. At the molecular level, studies have suggested 
that IRF4, together with BATF (basic leucine zipper transcription factor ATF-like) and the 
activator protein-1 family member JUN, acts as a ‘pioneer transcriptional factor’ that prepares 
chromatin accessibility for the subsequent lineage-specific transcriptional factor and drives 
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gene expression for the differentiation of effector T cells [8-10]. It has been documented that 
IRF4 is necessary for the differentiation of diverse effector CD4+ T cell subsets, including 
helper T cell (Th) types 2 [11-13], Th9 [14] and Th17 [6, 15, 16], follicular Th cells [17], the 
sustained effector function of cytotoxic T cells [18-20], the regulation of effector regulatory T 
cells (Tregs) [21], the series of developmental stages of B cells [17, 22-26] and the 
development and function of dendritic cells (DCs) [27-30]. 
IRF4 is thought to play a crucial role in the pathogenesis of autoimmune diseases, since the 
genetic deletion of IRF4 has been shown to abrogate several autoimmune diseases in mouse 
models, including experimental autoimmune encephalomyelitis [15], experimental colitis [31] 
and lupus nephritis [32]. Previous studies have suggested that a lack of IRF4 confers disease 
resistance due to failure of the specific differentiation of CD4+ T cells, especially Th17 cells, 
in models of autoimmune diseases including MRL/lpr mice and NOD mice [15, 32-34]. 
However, it is still unclear whether one or more specific Th subsets, such as Th17 cells, play a 
main role in autoimmune pathogenesis in type 1 diabetes, and we and others have reported 
that a lack of IL-17 does not alter diabetes susceptibility in NOD mice [35, 36]. 
Studies have indicated that IRF4 is essential for sustaining the differentiation of CD8+ T cells 
by regulating transcriptional factors that are crucial for effector generation (T-bet and 
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Blimp-1) [18, 19]. Furthermore, the expression of IRF4, which is regulated by antigen–T cell 
receptor (TCR) affinity, has also been reported to be required for the metabolic function and 
migratory behaviour of activated CD8+ T cells in a dose-dependent manner [20]. We therefore 
hypothesised that the dosage of IRF4 expression regulates autoimmune pathogenesis in NOD 
mice, mediated by autoreactive CD4+ and CD8+ T cells. 
To this end, we generated heterozygous and homozygous IRF4-deficient NOD mice and 
evaluated the influence of the genetic modification of IRF4 on the development of 
autoimmune diabetes, and on the effector function of CD4+ and CD8+ T cells in vivo and in 
vitro. 
Methods 
Mice NOD mice and NOD/severe combined immunodeficiency (SCID) mice were purchased 
from Clea Japan (Tokyo, Japan). IRF4-deficient mice had been previously generated [37]. 
These mice were maintained by breeding at the Laboratory Animal Center for Animal 
Research at Nagasaki University under specific pathogen-free conditions. Only female mice 
were used in this study. 
Establishment of IRF4-deficient NOD mice IRF4-deficient mice were backcrossed with 
NOD mice for 15 successive generations. These mice were selected by a PCR analysis of tail 
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DNA, as previously described [37, 38]. An analysis of the microsatellite markers of the 
diabetes susceptibility (Idd1-14) loci by PCR of the tail DNA, as previously described [38], 
showed that the mice were homozygous for all of the NOD alleles. Genotyping of 
chromosome 13 confirmed that the NOD/B6/129 polymorphic markers D13Mit80 (8.7 cM 
from IRF4 loci), D13Mit218 (21.8 cM), D13Mit163 (25.4 cM), D13Mit84 (25.7 cM) and 
D13Mit61 (Idd14) (41.0 cM) were all derived from the NOD background. 
Homozygous IRF4-deficient (Irf4−/−), heterozygous IRF4-deficient (Irf4+/−) and wild-type 
(WT) NOD mice were established by intercrossing heterozygotes of the 15th generation. All 
animal experiments described in this study were approved by the institutional animal 
experimentation committee and were conducted in accordance with the Guidelines for Animal 
Experimentation. 
Monitoring for spontaneous diabetes Mouse blood glucose levels were monitored for 
spontaneous diabetes using the OneTouch Ultra blood glucose monitoring system (Johnson & 
Johnson, Tokyo, Japan). Monitoring was conducted weekly when the mice were 12–20 weeks 
old and then every other week from 20 to 50 weeks of age. Monitoring was terminated when 
the mice became moribund. Mice with blood glucose levels of more than 13.9 mmol/l for two 
consecutive measurements were considered diabetic. 
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Measurement of serum IgG and insulin autoantibodies We performed an ELISA to 
measure IgG in the serum of mice at 4 weeks of age using the Mouse IgG ELISA Quantitation 
Set (Bethyl Laboratories, Montgomery, TX, USA). We evaluated the levels of insulin 
autoantibody (IAA) in serum using a 96-well filtration plate micro IAA assay, as previously 
described [39]. 
Histology Pancreatic sections from 18-week-old mice were histologically analysed by 
staining paraffin-embedded samples with hematoxylin and eosin. A minimum of 30 islets 
from each mouse were evaluated under a microscope by two different observers. The severity 
of insulitis was scored as follows: 0, no lymphocytic infiltration; 1, lymphocytic infiltration 
occupying <25% of the total islet cell area; 2, lymphocytic infiltration occupying 25–50% of 
the total islet cell area; 3, lymphocytic infiltration occupying 50–75% of the total islet cell 
area; 4, lymphocytic infiltration occupying >75% of the total islet cell area, or small retracted 
islets. 
Adoptive transfer experiments CD4+CD25− T cells or CD8+ T cells were purified from the 
spleens of 10- to 12-week-old prediabetic Irf4−/−, Irf4+/− and WT NOD mice using magnetic 
bead cell sorting (Miltenyi Biotech, Auburn, CA, USA). The purity of the CD4+CD25− and 
CD8+ T cells was at least 92% and 98%, respectively, as confirmed by flow cytometry 
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analysis. Purified CD4+CD25− (1.0×107) and CD8+ (0.5×107) T cells were combined and i.p. 
injected into 10-week-old NOD/SCID mice, and the mice were then monitored for blood 
glucose twice weekly after the adoptive transfer. 
Flow cytometric analysis Single-cell suspensions were prepared from mouse spleens, 
pancreatic lymph nodes and inguinal lymph nodes. Red blood cells were lysed in ammonium 
chloride buffer. For surface staining, cells were stained for 20 min with the corresponding 
fluorescent-labelled or biotin-conjugated antibodies against surface molecules: CD3e 
(145-2C11), CD4 (GK1.5), CD8 (53-6.7), B220 (RA3-6B2), CD44 (IM7), CD62L (MEL-14), 
I-Ag7 (I-Ak, 10-3.6) and CD11c (N418). 
For intracellular IRF4 staining of T cells, splenocytes (SPCs) were stimulated with 
plate-bound anti-CD3 (BD Biosciences/BD Pharmingen, San Diego, CA, USA) and soluble 
anti-CD28 (37.51) (2 μg/ml) (eBioscience, San Diego, CA, USA) for 36 h and then stained 
with phycoerythrin (PE)-conjugated anti-IRF4 (3E4) antibodies. For the intracellular cytokine 
staining, SPCs were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) and 
500 ng/ml ionomycin (both from Sigma, St Louis, MO, USA) in the presence of 2 µM 
monensin for 5 h. Thereafter, the cells were stained with allophycocyanin-conjugated 
anti-CD4, followed by intracellular staining with PE-Cy7-conjugated anti-IL-17 (eBio17B7) 
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and PerCP-Cy5.5-conjugated anti-IFN-γ (XMG1.2) antibodies (all from eBioscience). For 
intracellular IRF4 staining of DCs, cells were directly stained without culture. 
For intracellular staining of granzyme B and perforin, purified CD8+ T cells were activated 
with plate-bound anti-CD3 and anti-CD28 for 48 h, followed by incubation with recombinant 
mouse IL-2 (100 U/ml; eBioscience) for 72 h. Before intracellular staining, the activated 
CD8+ T cells were re-stimulated with PMA and ionomycin in the presence of monensin 
during the final 5 h. Thereafter, the cells were stained with PE-conjugated anti-granzyme B 
(16G6) and FITC-conjugated anti-perforin (eBioOMAK-D) antibodies. For intracellular 
forkhead box protein P3 (FOXP3) staining, cells were stained with FITC-conjugated 
anti-CD4 and PE-conjugated anti-CD25 (PC61), followed by intracellular FOXP3 staining 
with PE-Cy5-conjugated anti- FOXP3 (FJK-16s). All cells were analysed on a FACSCanto II 
flow cytometry system using FACSDiva software (BD Biosciences). 
Statistical analysis Data are expressed as means (SD). Group differences were analysed 
using Student’s t test. Differences between Kaplan–Meier survival curves were evaluated by 
the logrank test, using SPSS II software for Windows (SPSS Inc., Chicago, IL, USA). p 




IRF4 expression on T cells and DCs, lymphocyte numbers and IgG production We first 
assessed the expression of IRF4 in CD4+ and CD8+ T cells after TCR stimulation and in DCs 
without stimulation. T cells and DCs derived from Irf4−/− NOD mice were used as negative 
controls. The expression levels of IRF4 in T cells and DCs derived from Irf4+/− NOD mice 
were almost half those from WT NOD mice (mean fluorescent intensity [MFI] of CD4+ T 
cells: 3221±71 in WT vs 1806±209 in Irf4+/−; CD8+ T cells: 2255±234 in WT vs 1271±192 in 
Irf4+/−; DCs: 1014±83 in WT vs 720±70 in Irf4+/−; all p<0.01) (Fig. 1a–c).  
Since IRF4 knockout mice have been reported to have lymphadenopathy [37], we assessed 
the cell numbers of lymphocyte subsets in SPCs and pancreatic lymph nodes. Flow cytometric 
analysis revealed that, compared with WT NOD mice of the same age, 12-week-old Irf4−/− 
NOD mice had significantly increased numbers of lymphocytes, including CD3+, CD4+ and 
CD8+ T cells and B cells, but a slightly increased proportion of CD4+ T cells and a decreased 
proportion of CD8+ T cells (Table 1). In contrast, Irf4+/− NOD mice showed normal 
lymphocyte subset distribution and cellularity. 
We also found that IRF4 deficiency lowered the serum concentrations of IgG in a 
gene-dose-dependent manner in NOD mice (p<0.01) (Fig. 1d). 
Diabetes, insulitis and IAA levels in IRF4-deficient NOD mice To study the role of IRF4 in 
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the pathogenesis of autoimmune diabetes in NOD mice, we compared the incidence of 
diabetes from 12 to 50 weeks of age, the level of insulitis at 18 weeks and the level of IAA at 
12 weeks among female Irf4−/−, Irf4+/− and WT NOD mice. We found that Irf4−/− NOD mice 
were completely protected from the development of insulitis/diabetes, whereas littermate WT 
NOD mice showed the normal development of insulitis/diabetes as usually observed in our 
colony. Importantly, heterozygous IRF4 deficiency completely suppressed the development of 
diabetes, although minimal insulitis was observed in a small fraction of mice (Fig. 2a,b). IAA 
expression was absent in both Irf4+/− and Irf4−/− NOD mice (Fig. 2c). All of the Irf4−/− NOD 
mice, but not the Irf4+/− mice, became moribund after 40 weeks of age for unknown reasons. 
This type of early death is also sometimes observed in Irf4−/− non-NOD mice, and it is 
unlikely that their deaths are associated with autoimmunity. 
Adoptive transfer study with Treg-depleted effector T cells into NOD/SCID mice Type 1 
diabetes has been considered to be a T cell-mediated disease. The disease resistance induced 
by IRF4 deficiency may be due to attenuation of the effector function of T cells in NOD mice. 
To assess the effector function of IRF4-deficient T cells, we compared the development of 
adoptively transferred diabetes in recipient NOD/SCID mice that received combined 
Treg-depleted CD4+CD25− T cells (1.0×107) and CD8+ T cells (0.5×107) purified from SPCs 
of prediabetic Irf4−/−, Irf4+/− and WT NOD mice. Two-thirds (8/12) of the recipient mice 
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transferred with effector T cells from WT NOD mice rapidly developed diabetes, as expected, 
while the mice with Irf4−/− T cells did not develop diabetes until 50 days post-transfer (Fig. 3, 
p<0.05). The 25% of mice (3/12) transferred with T cells from Irf4+/− NOD mice developed 
diabetes, but with a significant reduction in diabetes incidence compared with mice 
transferred with WT T cells (Fig. 3, p<0.05). 
To investigate the respective effector functions of IRF4-deficient CD4+ and CD8+ T cells, we 
conducted an adoptive transfer experiment with combined CD4+CD25− and CD8+ T cell 
subsets alternately derived from Irf4−/− and WT NOD mice. Diabetes development was 
suppressed to 11% (1/9) in mice transferred with Irf4−/− CD4/Irf4+/+ CD8 subsets compared 
with mice with both subsets from WT NOD mice (Fig. 3, p<0.05). No diabetes was observed 
in mice with Irf4+/+ CD4/Irf4−/− CD8 subsets (Fig. 3). Histological analysis revealed that the 
severity of insulitis was not significantly different between recipient mice with 
Irf4−/−CD4/Irf4+/+CD8 and those with Irf4+/+CD4/Irf4−/−CD8 subsets (mean insulitis score at 
50 days after transfer: 2.02±1.66 in four mice with Irf4−/−CD4/Irf4+/+CD8 vs 2.14±0.77 in 
three mice with Irf4+/+CD4/Irf4−/−CD8, p=0.9). These results indicate that IRF4 plays a 




Flow cytometric analysis for CD4+, CD8+ T cells and DCs in IRF4-deficient NOD mice 
Because IRF4 affects the effector function of CD8+ as well of CD4+ T cells, we evaluated the 
phenotypes of each T subset. We first determined the expression of surface molecules, 
identifying memory and naive T cells, CD44 and CD62L, and the Treg population on CD4+ T 
cells without stimulation. We found that Irf4−/− NOD mice did not maintain T cell homeostasis, 
and that the populations of memory and naive T cells were significantly reduced in Irf4−/− 
compared with WT NOD mice. However, the populations of memory and naive T cells in 
Irf4+/− mice were equivalent to those in WT NOD mice (Fig. 4a–c,g). With regard to Tregs, 
the percentages of CD4+CD25+FOXP3+ T cells were significantly reduced in Irf4−/− and 
Irf4+/− NOD mice in a gene-dose-dependent manner (9.7±0.8% in WT vs 7.8±0.4% in Irf4+/− 
and 4.3±0.5% in Irf4−/− NOD mice, p<0.01) (Fig. 4d–f,h). 
We next evaluated cytokine expression in CD4+ T cells by intracellular staining after 
stimulation. As previously observed in Irf4−/− C57BL/6 mice [15], the percentage of 
IL-17-producing CD4+ T cells was significantly reduced in stimulated SPCs derived from 
Irf4−/− NOD mice, while the percentages of IL-17-positive cells from Irf4+/− NOD mice were 
almost equal to those from WT NOD mice. In contrast, the percentages of IFN-γ-producing 
cells did not significantly differ among the three groups (Fig. 5a–c,g). We also assessed the 
effector molecules of cytotoxic T cells, granzyme B and perforin, in purified CD8+ T cells 
17 
 
after TCR stimulation followed by incubation with IL-2. The production of granzyme B and 
perforin were severely impaired in Irf4−/−, but not in Irf4+/−, CD8+ T cells compared with WT 
CD8+ T cells (Fig. 5d–f,h).  
Because IRF4 also plays an important role in the development and function of dendritic 
subsets, we next evaluated DCs in NOD mice. The proportion of CD4+ DCs in the spleen was 
reduced in Irf4−/− compared with WT NOD mice, as has been previously reported in Irf4−/− 
non-NOD mice [27]. This reduction was not, however, significant in Irf4+/− NOD mice (Fig. 
6a–f,j). In the lymph nodes, the proportion of migratory (m)DC (MHC-IIhiCD11cint) was 
reduced in Irf4−/− compared with WT NOD mice, as has also been reported in Irf4−/− 
non-NOD mice [29, 30]. Interestingly, the proportion of mDCs in the lymph nodes of Irf4+/− 
NOD mice was intermediate between the other two strains, suggesting that the mDC 
proportion is dependent on the dose of the Irf4 gene (Fig. 6g–i,k). 
Discussion 
In this study, we determined the impact of the genetic deletion of IRF4 in NOD mice on the 
pathogenesis of type 1 diabetes. We found that Irf4−/− NOD mice were completely protected 
from spontaneous diabetes, insulitis and autoantibody production, indicating that IRF4 is a 
crucial transcriptional factor in the development of autoimmune diabetes in NOD mice, as has 
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been reported for other autoimmune diseases [15, 31-33]. Compared with WT NOD mice, the 
spleens and lymph nodes of Irf4−/− NOD mice had phenotypes of lymphadenopathy, including 
larger size, an increased number of T and B cells and dysregulated naive/memory CD4+ T cell 
populations. Severe hypogammaglobulinaemia was also observed in Irf4−/− NOD mice. These 
phenotypes are consistent with a previous report of Irf4−/− mice of non-NOD background [37].  
Our adoptive transfer study with effector Irf4−/− T cells showed the complete suppression of 
diabetes in recipient mice. These findings indicate that total elimination of IRF4 in T and B 
cells leads to their dysregulated function and diminishment of the intrinsic effector function of 
T cells that is associated with the development of diabetes in NOD mice. Our findings also 
revealed that: (1) total elimination of IRF4 abrogated the expression of effector molecules of 
CD8+ T cells after stimulation; and (2) deletion of IRF4 in CD8+ T cells protected recipient 
mice from rapid progression of diabetes. These results indicate that the expression of IRF4 is 
indispensable not only in CD4+ T cells, but also in CD8+ T cells, for the development of 
insulitis/diabetes in NOD mice. 
Of note, Irf4+/– mice showed complete resistance against diabetes development in our study. 
This is the first report to identify the importance of haploinsufficiency of IRF4 for disease 
resistance in autoimmune disease. This finding is highly critical from a clinical point of view, 
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as it suggests the importance of subtle differences in IRF4 expression due to gene 
polymorphisms such as SPI1 for disease development or activity in systemic lupus 
erythematosus [40]. Similar results have been demonstrated in studies of mitogen-inducible 
gene 6 protein in streptozotocin-induced diabetes and in our previous study of IL-17 in 
autoimmune thyroiditis in NOD-H2h4 mice [41, 42]. 
Currently, IRF4 is considered to be a key component that translates TCR affinity or the 
strength of TCR signalling into the functions of activated CD8+ T cells, including their 
differentiation and expansion in a dose-dependent manner [20, 43]. Interestingly, this 
gene-dose effect was evident in IRF4-haploinsufficient CD8+ T cells. When Irf4−/−, Irf4+/− 
and WT CD8+ T cells were transferred into the same mice and activated in vivo, clonal 
expansion was most robust in Irf4+/+ CD8+ T cells, followed by ifr4+/– and by Irf4–/– CD8+ T 
cells [20]. Consistent with these data, our adoptive transfer study showed that IRF4 deficiency 
in effector T cells conferred disease resistance in recipient mice in a gene-dose-dependent 
manner. These results suggest that the dosage of IRF4 affects the function of autoreactive 
CD8+ T cells, or possibly CD4+ T cells, which is associated with diabetes susceptibility in 
NOD mice. 
Despite the partial deficit of diabetogenicity in Irf4+/− effector T cells, Irf4+/− NOD mice did 
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not develop diabetes, and the mechanisms behind this are not completely explained by defects 
in T cells. We therefore investigated the phenotype of DCs, since previous reports have 
demonstrated that lack of IRF4 impairs the development of CD8–CD11b+ DCs in the spleen 
[27, 28] and reduces the recruitment of mDCs to draining lymph nodes [29, 30]. Interestingly, 
haploinsufficiency of IRF4 did not affect the development of CD4+ DCs in the spleen, but did 
reduce the proportion of mDCs in lymph nodes. These results suggest that IRF4 deficiency 
impairs the migratory function of DCs to draining lymph nodes in a gene-dose-dependent 
manner, and that this deficit in DC function could play a role in the complete disease 
resistance of Irf4+/− NOD mice. 
Clinical intervention trials conducted with patients with recent-onset type 1 diabetes and using 
targeted immunotherapy to T and B cells have demonstrated transiently reserved residual 
insulin productivity [44-47], although the treatments did not appear to fundamentally alter the 
overall disease course. Our study of IRF4-deficient NOD mice clarifies the important role of 
IRF4 in regulating T cells, DCs and possibly other cells in the pathogenesis of autoimmune 
diabetes, and our results demonstrate that the partial elimination of IRF4 fully suppresses the 
development of insulitis/diabetes in NOD mice. All of these findings indicate that IRF4 could 




We thank M. Motomura, Y. Ohyama, M. Tanaka, H. Kawachi and S. Chuganji (Nagasaki 
University, Nagasaki, Japan) for technical assistance. 
Funding 
This study was supported by research grants from the Japan Society for the Promotion of 
Science (Nos 23791036 and 24591334). 
Duality of interest 
The authors declare that there is no duality of interest related to this study. 
Contribution statement 
All authors contributed to the conception and design of the study; acquisition, analysis and 
interpretation of data; and drafting and editing of the manuscript. All of the authors approved 
the final version of the manuscript. SA, MK and NA had full access to all of the data in the 
study and take responsibility for the integrity of the data and the accuracy of the data analysis. 
References 
[1] Atkinson MA, Maclaren NK (1994) The pathogenesis of insulin-dependent diabetes 
mellitus. N Engl J Med 331: 1428-1436 
[2] Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical 
interventions in type 1 diabetes. Nature 464: 1293-1300 
22 
 
[3] Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune 
dysregulation. Annu Rev Immunol 23: 447-485 
[4] Tamura T, Yanai H, Savitsky D, Taniguchi T (2008) The IRF family transcription 
factors in immunity and oncogenesis. Annu Rev Immunol 26: 535-584 
[5] Matsuyama T, Grossman A, Mittrucker HW, et al. (1995) Molecular cloning of 
LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the 
interferon-stimulated response element (ISRE). Nucleic Acids Res 23: 2127-2136 
[6] Biswas PS, Bhagat G, Pernis AB (2010) IRF4 and its regulators: evolving insights 
into the pathogenesis of inflammatory arthritis? Immunol Rev 233: 79-96 
[7] Huber M, Lohoff M (2014) IRF4 at the crossroads of effector T cell fate decision. 
Eur J Immunol 44: 1886-1895 
[8] Glasmacher E, Agrawal S, Chang AB, et al. (2012) A genomic regulatory element 
that directs assembly and function of immune-specific AP-1-IRF complexes. Science 338: 
975-980 
[9] Li P, Spolski R, Liao W, et al. (2012) BATF-JUN is critical for IRF4-mediated 
transcription in T cells. Nature 490: 543-546 
[10] Murphy TL, Tussiwand R, Murphy KM (2013) Specificity through cooperation: 
BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol 13: 499-509 
[11] Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH (2002) 
Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene 
expression. J Exp Med 195: 1003-1012 
[12] Lohoff M, Mittrucker HW, Prechtl S, et al. (2002) Dysregulated T helper cell 
differentiation in the absence of interferon regulatory factor 4. Proceedings of the National 
Academy of Sciences of the United States of America 99: 11808-11812 
[13] Tominaga N, Ohkusu-Tsukada K, Udono H, Abe R, Matsuyama T, Yui K (2003) 
Development of Th1 and not Th2 immune responses in mice lacking IFN-regulatory factor-4. 
International immunology 15: 1-10 
[14] Staudt V, Bothur E, Klein M, et al. (2010) Interferon-regulatory factor 4 is essential 
for the developmental program of T helper 9 cells. Immunity 33: 192-202 
[15] Brustle A, Heink S, Huber M, et al. (2007) The development of inflammatory 
T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 8: 958-966 
23 
 
[16] Huber M, Brustle A, Reinhard K, et al. (2008) IRF4 is essential for IL-21-mediated 
induction, amplification, and stabilization of the Th17 phenotype. Proceedings of the National 
Academy of Sciences of the United States of America 105: 20846-20851 
[17] Bollig N, Brustle A, Kellner K, et al. (2012) Transcription factor IRF4 determines 
germinal center formation through follicular T-helper cell differentiation. Proceedings of the 
National Academy of Sciences of the United States of America 109: 8664-8669 
[18] Yao S, Buzo BF, Pham D, et al. (2013) Interferon regulatory factor 4 sustains CD8+ T 
cell expansion and effector differentiation. Immunity 39: 833-845 
[19] Raczkowski F, Ritter J, Heesch K, et al. (2013) The transcription factor interferon 
regulatory factor 4 is required for the generation of protective effector CD8+ T cells. 
Proceedings of the National Academy of Sciences of the United States of America 110: 
15019-15024 
[20] Man K, Miasari M, Shi W, et al. (2013) The transcription factor IRF4 is essential for 
TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat Immunol 
14: 1155-1165 
[21] Cretney E, Xin A, Shi W, et al. (2011) The transcription factors Blimp-1 and IRF4 
jointly control the differentiation and function of effector regulatory T cells. Nat Immunol 12: 
304-311 
[22] Ochiai K, Maienschein-Cline M, Simonetti G, et al. (2013) Transcriptional regulation 
of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity 38: 
918-929 
[23] Johnson K, Hashimshony T, Sawai CM, et al. (2008) Regulation of immunoglobulin 
light-chain recombination by the transcription factor IRF-4 and the attenuation of 
interleukin-7 signaling. Immunity 28: 335-345 
[24] Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H (2006) Graded 
expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell 
differentiation. Immunity 25: 225-236 
[25] Klein U, Casola S, Cattoretti G, et al. (2006) Transcription factor IRF4 controls 
plasma cell differentiation and class-switch recombination. Nat Immunol 7: 773-782 
[26] Willis SN, Good-Jacobson KL, Curtis J, et al. (2014) Transcription factor IRF4 
regulates germinal center cell formation through a B cell-intrinsic mechanism. Journal of 
immunology 192: 3200-3206 
24 
 
[27] Suzuki S, Honma K, Matsuyama T, et al. (2004) Critical roles of interferon 
regulatory factor 4 in CD11bhighCD8α– dendritic cell development. Proceedings of the 
National Academy of Sciences of the United States of America 101: 8981-8986 
[28] Tamura T, Tailor P, Yamaoka K, et al. (2005) IFN regulatory factor-4 and -8 govern 
dendritic cell subset development and their functional diversity. Journal of immunology 174: 
2573-2581 
[29] Akbari M, Honma K, Kimura D, et al. (2014) IRF4 in dendritic cells inhibits IL-12 
production and controls Th1 immune responses against Leishmania major. Journal of 
immunology 192: 2271-2279 
[30] Bajana S, Roach K, Turner S, Paul J, Kovats S (2012) IRF4 promotes cutaneous 
dendritic cell migration to lymph nodes during homeostasis and inflammation. Journal of 
immunology 189: 3368-3377 
[31] Mudter J, Amoussina L, Schenk M, et al. (2008) The transcription factor IFN 
regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. The Journal 
of clinical investigation 118: 2415-2426 
[32] Lech M, Weidenbusch M, Kulkarni OP, et al. (2011) IRF4 deficiency abrogates lupus 
nephritis despite enhancing systemic cytokine production. J Am Soc Nephrol 22: 1443-1452 
[33] Biswas PS, Gupta S, Chang E, et al. (2010) Phosphorylation of IRF4 by ROCK2 
regulates IL-17 and IL-21 production and the development of autoimmunity in mice. The 
Journal of clinical investigation 120: 3280-3295 
[34] Biswas PS, Gupta S, Chang E, Bhagat G, Pernis AB (2011) Aberrant ROCK 
activation promotes the development of type I diabetes in NOD mice. Cell Immunol 266: 
111-115 
[35] Joseph J, Bittner S, Kaiser FM, Wiendl H, Kissler S (2012) IL-17 silencing does not 
protect nonobese diabetic mice from autoimmune diabetes. Journal of immunology 188: 
216-221 
[36] Kuriya G, Uchida T, Akazawa S, et al. (2013) Double deficiency in IL-17 and IFN-γ 
signalling significantly suppresses the development of diabetes in the NOD mouse. 
Diabetologia 56: 1773-1780 
[37] Mittrucker HW, Matsuyama T, Grossman A, et al. (1997) Requirement for the 




[38] Serreze DV, Chapman HD, Varnum DS, et al. (1996) B lymphocytes are essential for 
the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” 
stock of NOD.Igμnull mice. J Exp Med 184: 2049-2053 
[39] Yu L, Robles DT, Abiru N, et al. (2000) Early expression of antiinsulin 
autoantibodies of humans and the NOD mouse: evidence for early determination of 
subsequent diabetes. Proceedings of the National Academy of Sciences of the United States of 
America 97: 1701-1706 
[40] Hikami K, Kawasaki A, Ito I, et al. (2011) Association of a functional polymorphism 
in the 3'-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis and 
rheumatism 63: 755-763 
[41] Ahyi AN, Chang HC, Dent AL, Nutt SL, Kaplan MH (2009) IFN regulatory factor 4 
regulates the expression of a subset of Th2 cytokines. Journal of immunology 183: 1598-1606 
[42] Horie I, Abiru N, Nagayama Y, et al. (2009) T helper type 17 immune response plays 
an indispensable role for development of iodine-induced autoimmune thyroiditis in nonobese 
diabetic-H2h4 mice. Endocrinology 150: 5135-5142 
[43] Nayar R, Schutten E, Bautista B, et al. (2014) Graded levels of IRF4 regulate CD8+ T 
cell differentiation and expansion, but not attrition, in response to acute virus infection. 
Journal of immunology 192: 5881-5893 
[44] Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. (2005) Insulin needs after 
CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608 
[45] Keymeulen B, Walter M, Mathieu C, et al. (2010) Four-year metabolic outcome of a 
randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on 
their age and baseline residual beta cell mass. Diabetologia 53: 614-623 
[46] Orban T, Bundy B, Becker DJ, et al. (2014) Costimulation modulation with abatacept 
in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. 
Diabetes Care 37: 1069-1075 
[47] Pescovitz MD, Greenbaum CJ, Bundy B, et al. (2014) B-lymphocyte depletion with 






Fig. 1  (a) Expression of IRF4 in CD4+ T cells, CD8+ T cells and DCs. SPCs from WT (red), 
Irf4+/− (green) and Irf4−/− (blue) NOD littermates were stimulated with anti-CD3/CD28 
monoclonal antibodies and stained for CD4, CD8 and IRF4. IRF4 profiles of CD4+ and CD8+ 
cells are shown (left and centre). SPCs were stained for CD11c/I-Ag7, and IRF4 profiles of 
CD11c+I-Ag7+ cells are shown (right). MFI of IRF4 staining in (b) CD4+ and CD8+ T cells and 
(c) DCs derived from WT (black bars), Irf4+/− (grey bars) and Irf4−/− NOD littermates (white 
bars). Data are means±SD (n=3–5). (d) Serum IgG from female WT, Irf4+/− and Irf4−/− NOD 
littermates (n=10 per group) was evaluated with ELISA. **p<0.01 
Fig. 2 Diabetes, insulitis and IAAs in WT, Irf4+/− and Irf4−/− NOD mice. (a) Incidence of 
diabetes in WT (squares, n=40), Irf4+/− (triangles, n=30) and Irf4−/− (circles, n=40) NOD 
littermates. (b) Severity of insulitis in WT, Irf4+/− and Irf4−/− NOD littermates at 18 weeks of 
age (n=5 per group). Insulitis levels: 0 (white), 1 (light grey), 2 (dark grey), 3 (horizontal 
stripes) and 4 (black). (c) Levels of serum IAA in WT, Irf4+/− and Irf4−/− NOD littermates at 
12 weeks of age (n=10 per group). The index value of 0.01 was applied as the cut-off limit. 




Fig. 3 Adoptive transfer of purified CD4+CD25− T cells (1.0×107) and CD8+ T cells 
(0.5×107) from WT, Irf4+/− and Irf4−/− NOD mice into NOD/SCID mice. Recipient mice were 
divided into five groups according to the combination of transfer subsets: WT CD4+CD25− T 
cells + WT CD8+ T cells (n=12, squares); Irf4+/− CD4+CD25− T cells + Irf4+/− CD8+ T cells 
(n=12, triangles); Irf4−/− CD4+CD25− T cells + Irf4−/− CD8+ T cells (n=5, circles); Irf4−/− 
CD4+CD25− T cells + WT CD8+ T cells (n=9, black diamonds); and WT CD4+CD25− T cells 
+ Irf4−/− CD8+ T cells (n=9, white diamonds). Error bars: SE. *p<0.05, **p<0.01 using the 
logrank test vs the subgroup that received both subsets from WT NOD mice 
Fig. 4 Activation markers and FOXP3+CD25+ cells in CD4+ T cells. Representative staining 
of CD4+ SPCs for (a–c) CD44 and CD62L and (d–f) CD25 and FOXP3. Quantification of (g) 
CD44lowCD62Lhi, CD44hiCD62Lhi and CD44hiCD62Llow cells and (h) CD25+FOXP3+ cells in 
WT (black bars), Irf4+/− (grey bars) and Irf4−/− (white bars) NOD littermates. Data are means 
± SD (n=5). **p<0.01 
Fig. 5 IFN-γ+/IL-17+ cells in CD4+ T cells and effector molecules in CD8+ T cells. (a–c) 
Representative staining of CD4+ SPCs for intracellular IFN-γ and/or IL-17. (d–f) Purified 
CD8+ T cells were stimulated as mentioned in the Methods section. Representative data for 
the intracellular expression of granzyme B and perforin are shown. Quantification of (g) 
28 
 
IFN-γ- and IL-17-positive cells and (h) granzyme B- and perforin-positive cells in WT (black 
bars), Irf4+/− (grey bars) and Irf4−/− (white bars) NOD littermates. Data are means±SD (n=5). 
*p<0.05, **p<0.01 
Fig. 6 DC subsets in spleen and peripheral lymph nodes. (a–f) SPCs were stained for CD11c, 
I-Ag7, CD4 and CD8. (a–c) CD11c/I-Ag7 profiles and (d–f) CD4/CD8 profiles of DCs 
(CD11c+I-Ag7+). The numbers in the profiles indicate the proportions in the square (a–c) or in 
each quadrant (d–f). (g–i) Cells from inguinal lymph nodes were stained for CD11c and I-Ag7, 
and the proportions (%) of mDCs (I-Ag7hiCD11cint) are indicated. Populations of DC subsets 
in (j) spleen and (k) inguinal lymph nodes of WT (black bars), Irf4+/− (grey bars) and Irf4−/− 
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